This company has been acquired
Apexigen Past Earnings Performance
Past criteria checks 0/6
Apexigen has been growing earnings at an average annual rate of 17%, while the Biotechs industry saw earnings growing at 17.4% annually.
Key information
17.0%
Earnings growth rate
57.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Apexigen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -27 | 13 | 15 |
| 31 Mar 23 | 0 | -29 | 11 | 19 |
| 31 Dec 22 | 0 | -32 | 10 | 23 |
| 30 Sep 22 | 0 | -34 | 9 | 25 |
| 30 Jun 22 | 0 | -33 | 7 | 25 |
| 31 Mar 22 | 0 | -31 | 8 | 24 |
| 31 Dec 21 | 0 | -29 | 7 | 22 |
Quality Earnings: APGN is currently unprofitable.
Growing Profit Margin: APGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if APGN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare APGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: APGN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.